Oaktree Acquisition Corp. III Life Sciences ownership disclosure: Fort Baker Capital Management LP and affiliated reporting persons state they beneficially own 1,000,000 Class A ordinary shares, representing 5.1% of the class. The filing cites 19,783,010 shares outstanding as of March 26, 2026. The reported holdings reflect shared voting and shared dispositive power over 1,000,000 shares; sole voting and dispositive power are reported as 0. The reporting persons say they are filing jointly but disclaim membership in a group and disclaim beneficial ownership except to the extent of any pecuniary interest.
Oaktree Acquisition Corp. III Life Sciences ownership disclosure: Fort Baker Capital Management LP and affiliated reporting persons state they beneficially own 1,000,000 Class A ordinary shares, representing 5.1% of the class. The filing cites 19,783,010 shares outstanding as of March 26, 2026. The reported holdings reflect shared voting and shared dispositive power over 1,000,000 shares; sole voting and dispositive power are reported as 0. The reporting persons say they are filing jointly but disclaim membership in a group and disclaim beneficial ownership except to the extent of any pecuniary interest.
Oaktree Acquisition Corp. III Life Sciences reported net income of $1,394,121 for the quarter ended March 31, 2026, driven by $1,850,659 of interest on cash held in its trust account and offset by $456,538 of general and administrative expenses.
Cash in the trust account reached $203,414,191, reflecting accretion of the redeemable Class A shares to a redemption value of $10.60 per share for 19,199,029 shares. The company held $1,276,930 of cash outside the trust and reported a working capital deficit of $207,947.
The SPAC has not yet selected a business combination target and continues to incur costs pursuing an acquisition. Management discloses that the need for additional capital, the October 25, 2026 deadline to complete a business combination, and the possibility of mandatory liquidation raise substantial doubt about its ability to continue as a going concern.
Oaktree Acquisition Corp. III Life Sciences reported net income of $1,394,121 for the quarter ended March 31, 2026, driven by $1,850,659 of interest on cash held in its trust account and offset by $456,538 of general and administrative expenses.
Cash in the trust account reached $203,414,191, reflecting accretion of the redeemable Class A shares to a redemption value of $10.60 per share for 19,199,029 shares. The company held $1,276,930 of cash outside the trust and reported a working capital deficit of $207,947.
The SPAC has not yet selected a business combination target and continues to incur costs pursuing an acquisition. Management discloses that the need for additional capital, the October 25, 2026 deadline to complete a business combination, and the possibility of mandatory liquidation raise substantial doubt about its ability to continue as a going concern.
THE GOLDMAN SACHS GROUP, INC. and Goldman Sachs & Co. LLC report shared beneficial ownership of 1,228,500 Class A ordinary shares of OAKTREE ACQUISITION CORP III LIFE SCIENCES. The filing states this position represents 6.2% of the class as shown on the cover page, with related joint filing and subsidiary attribution disclosures.
THE GOLDMAN SACHS GROUP, INC. and Goldman Sachs & Co. LLC report shared beneficial ownership of 1,228,500 Class A ordinary shares of OAKTREE ACQUISITION CORP III LIFE SCIENCES. The filing states this position represents 6.2% of the class as shown on the cover page, with related joint filing and subsidiary attribution disclosures.
Oaktree Acquisition Corp. III Life Sciences files its Annual Report outlining its structure and strategy as a Cayman Islands–incorporated, healthcare-focused special purpose acquisition company. It is a blank check company formed in June 2024 to complete an initial business combination.
The company plans to merge with biopharma, medical device, diagnostics or specialized healthcare services businesses in North America, the UK and Western Europe, leveraging its affiliation with Oaktree, which had $223 billion in assets under management as of December 31, 2025. Oaktree’s life sciences platform has committed about $6.2 billion across 54 investments since 2013.
As of December 31, 2025, the SPAC had $201,563,532 available to fund a deal and must complete a business combination within 24 months of its IPO, with potential extensions up to 36 months. The report details sponsor economics, potential conflicts of interest, warrant and share lock-up terms, and the requirement that any target (or targets) have an aggregate fair market value of at least 80% of net assets held in trust at signing.
Oaktree Acquisition Corp. III Life Sciences files its Annual Report outlining its structure and strategy as a Cayman Islands–incorporated, healthcare-focused special purpose acquisition company. It is a blank check company formed in June 2024 to complete an initial business combination.
The company plans to merge with biopharma, medical device, diagnostics or specialized healthcare services businesses in North America, the UK and Western Europe, leveraging its affiliation with Oaktree, which had $223 billion in assets under management as of December 31, 2025. Oaktree’s life sciences platform has committed about $6.2 billion across 54 investments since 2013.
As of December 31, 2025, the SPAC had $201,563,532 available to fund a deal and must complete a business combination within 24 months of its IPO, with potential extensions up to 36 months. The report details sponsor economics, potential conflicts of interest, warrant and share lock-up terms, and the requirement that any target (or targets) have an aggregate fair market value of at least 80% of net assets held in trust at signing.
Oaktree Acquisition Corp I-A received an updated ownership report from Barclays PLC, which filed an amended Schedule 13G/A as of December 31, 2025. Barclays reported beneficial ownership of 861,625 common shares, representing 4.35% of the class.
Barclays reported sole voting and sole dispositive power over all 861,625 shares, with no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Oaktree Acquisition Corp I-A received an updated ownership report from Barclays PLC, which filed an amended Schedule 13G/A as of December 31, 2025. Barclays reported beneficial ownership of 861,625 common shares, representing 4.35% of the class.
Barclays reported sole voting and sole dispositive power over all 861,625 shares, with no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report shared beneficial ownership of 803,487 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences, representing 4.1% of the class. Both reporting persons indicate zero sole voting and dispositive power and shared voting and dispositive power of 803,487, showing the stake is held jointly rather than under exclusive control by either entity.
The filing states the securities are held in the ordinary course of business and were not acquired to change or influence control. A joint filing agreement is attached and an exhibit clarifies that The Goldman Sachs Group, Inc. is a parent holding company and Goldman Sachs & Co. LLC is a subsidiary broker-dealer and registered investment adviser. The filing is classified as ownership of 5% or less of the class.
Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to complete a business combination; it has not selected a target. The company completed its Initial Public Offering and private placement and holds $197,576,768 in a Trust Account as of June 30, 2025, intended to fund a Business Combination. For the six months ended June 30, 2025 the company reported $3,533,134 net income, driven by $4,247,746 of interest income on Trust Account funds and offset by $714,612 of general and administrative expenses.
Outside the Trust Account the company had $1,385,359 in cash and $441,907 of working capital. There were 19,199,029 Class A shares subject to possible redemption at a redemption value of $10.29 per share. Material items include a $6,719,660 deferred underwriting fee payable from the Trust Account and sponsor provisions that may require the sponsor to indemnify the Trust Account, although the company notes the sponsor's only assets may be company securities. The company experienced a management change with the CFO resigning and a successor appointed on June 3, 2025.